Estelamari Rodriguez, MD, MPH, is the associate director of community outreach for thoracic oncology and the assistant ...
The once-daily oral drug improves patients’ lives while maintaining early, durable, and central nervous system responses, ...
Bridging therapy was administered to 90% of apheresed patients, with chemotherapy ± radiotherapy used in 53% and targeted ...
FDA approval establishes setmelanotide as the first labeled option for acquired hypothalamic obesity, addressing a population ...
Maria Hordinsky, MD, discusses exciting results in alopecia areata, including some discussed at the Winter Clinical ...
In this episode, ‘Assessing Clinical and Economic Factors in Treatment Selection and Payer Decision-Making,’ the panelists ...
Across treatment classes, CH associated with increased therapy-related cytopenias, particularly neutropenia, and DNMT3A/TET2 ...
Accelerated approval of semaglutide 7.2 mg establishes a higher-dose, once-weekly GLP-1 RA option for long-term weight ...
Survival in myeloma is clearly being prolonged,” says Mikhael. “Whereas historically, we saw a greater impact in younger ...
Pulmonary expert Noah Greenspan, DPT, discusses long COVID, early pandemic uncertainty, and how vaccination may help reduce ...
NHANES 2017–2018 elastography data (n=4102) linked to mortality showed 59 deaths over ~24 months; decedents were older and more likely to have diabetes. MASLD (CAP ≥274 dB/m) with diabetes carried ...
This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results